Novel drug-regulated transcriptional networks in brain reveal pharmacological properties of psychotropic drugs
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Despite their widespread use, the biological mechanisms underlying the efficacy of psychotropic drugs are still incompletely known; improved understanding of these is essential for development of novel more effective drugs and rational design of therapy. Given the large number of psychotropic drugs available and their differential pharmacological effects, it would be important to establish specific predictors of response to various classes of drugs. RESULTS: To identify the molecular mechanisms that may initiate therapeutic effects, whole-genome expression profiling (using 324 Illumina Mouse WG-6 microarrays) of drug-induced alterations in the mouse brain was undertaken, with a focus on the time-course (1, 2, 4 and 8 h) of gene expression changes produced by eighteen major psychotropic drugs: antidepressants, antipsychotics, anxiolytics, psychostimulants and opioids. The resulting database is freely accessible at http://www.genes2mind.org. Bioinformatics approaches led to the identification of three main drug-responsive genomic networks and indicated neurobiological pathways that mediate the alterations in transcription. Each tested psychotropic drug was characterized by a unique gene network expression profile related to its neuropharmacological properties. Functional links that connect expression of the networks to the development of neuronal adaptations (MAPK signaling pathway), control of brain metabolism (adipocytokine pathway), and organization of cell projections (mTOR pathway) were found. CONCLUSIONS: The comparison of gene expression alterations between various drugs opened a new means to classify the different psychoactive compounds and to predict their cellular targets; this is well exemplified in the case of tianeptine, an antidepressant with unknown mechanisms of action. This work represents the first proof-of-concept study of a molecular classification of psychoactive drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566 · cited 3×
“The relatively long half-lives of the mRNAs generated from these genes most likely contribute to the regulation of neural cell metabolism [20]; interestingly, patients with affective disorders often display altered brain metabolism [50].”
The size and burden of mental disorders and other disorders of the brain in Europe 2010
Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jönsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.018 · Cited by 3,754
NEURAL MECHANISMS OF ADDICTION: The Role of Reward-Related Learning and Memory
Hyman, S. E., Malenka, R. C., & Nestler, E. J. (2006) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.29.051605.113009 · Cited by 2,647
Animal models of neuropsychiatric disorders
Nestler, E. J., & Hyman, S. E. (2010) · Nature Neuroscience · doi:10.1038/nn.2647 · Cited by 2,023 · cited 1×
“Thus, despite the limitations of an animal model [17], the comparison of drug-induced dynamic alterations in the rodent striatal gene expression profile provides insights into molecular mechanisms of psychotropic drug actions.”
Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling
Lüscher, C., & Malenka, R. C. (2011) · Neuron · doi:10.1016/j.neuron.2011.01.017 · Cited by 1,105 · cited 1×
“It is thought that therapeutic agents reverse disease-related alterations by reconstruction and normalization of neuronal connections in targeted brain areas [5,6].”
Sharova, L. V., Sharov, A. A., Nedorezov, T., Piao, Y., Shaik, N., & Ko, M. S. H. (2009) · DNA Research · doi:10.1093/dnares/dsn030 · Cited by 591 · cited 1×
“Published databases [18,19,82] were used to check cell-type enrichment, mRNA half-life and to control for over-representation of TFBSs of genes [18,19,82].”
ΔFosB in brain reward circuits mediates resilience to stress and antidepressant responses
Vialou, V., Robison, A. J., LaPlant, Q. C., Covington, H. E., Dietz, D. M., Ohnishi, Y. N., Mouzon, E., Rush, A. J., Watts, E. L., Wallace, D. L., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2551 · Cited by 479
A negative regulator of MAP kinase causes depressive behavior
Duric, V., Banasr, M., Licznerski, P., Schmidt, H. D., Stockmeier, C. A., Simen, A. A., Newton, S. S., & Duman, R. S. (2010) · Nature Medicine · doi:10.1038/nm.2219 · Cited by 412
McEwen, B. S., Chattarji, S., Diamond, D. M., Jay, T. M., Reagan, L. P., Svenningsson, P., & Fuchs, E. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.80 · Cited by 406 · cited 2×
“Tianeptine is a tricyclic antidepressant whose mechanism of action is still not clear [24].”
Personalized Medicine for Depression: Can We Match Patients With Treatments?
Simon, G. E., & Perlis, R. H. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09111680 · Cited by 365 · cited 2×
“This diversity reflects their diverse pharmacological and neurobiological mechanisms of action [12], as well as significant differences in the efficacy of individual compounds in the treatment of different forms of depression [2,59].”
Research works printed but not linked: 60
- 10.1016/j.biopsych.2009.08.026 · DOI · Paper page
- 10.2174/138161211795164086 · DOI · Paper page
- 10.1126/science.8066450 · DOI · Paper page
- 10.1176/appi.ajp.2009.10030434 · DOI · Paper page
- 10.2174/138161209788168001 · DOI · Paper page
- 10.1016/S0006-3223(01)01267-7 · DOI · Paper page
- 10.1016/j.pneurobio.2011.05.007 · DOI · Paper page
- 10.1371/journal.pgen.0030059 · DOI · Paper page
- 10.1523/JNEUROSCI.4178-07.2008 · DOI · Paper page
- 10.1371/journal.pone.0012465 · DOI
- 10.1126/scitranslmed.3001318 · DOI · Paper page
- 10.1126/scitranslmed.3002648 · DOI · Paper page
- 10.1126/science.1132939 · DOI · Paper page
- 10.1177/107385840000600408 · DOI · Paper page
- 10.1186/gb-2007-8-6-r128 · DOI
- 10.1111/j.1601-183X.2007.00338.x · DOI
- 10.1016/j.biopsych.2005.01.022 · DOI
- 10.1186/1471-2202-11-152 · DOI
- 10.1007/s00213-003-1579-7 · DOI
- 10.1073/pnas.89.10.4270 · DOI · Paper page
- 10.1111/j.1601-183X.2012.00777.x · DOI
- 10.1523/JNEUROSCI.4588-08.2009 · DOI · Paper page
- 10.1523/JNEUROSCI.4554-11.2011 · DOI · Paper page
- 10.1096/fj.09-151423 · DOI
- 10.1126/science.1208049 · DOI · Paper page
- 10.1038/85138 · DOI · Paper page
- 10.1016/j.neuron.2004.07.019 · DOI · Paper page
- 10.1016/j.conb.2004.04.001 · DOI · Paper page
- 10.1387/ijdb.072355th · DOI
- 10.1523/JNEUROSCI.6421-09.2010 · DOI
- 10.1152/physrev.00013.2009 · DOI · Paper page
- 10.1042/BJ20060125 · DOI · Paper page
- 10.2337/db11-0120 · DOI · Paper page
- 10.1074/jbc.M312253200 · DOI
- 10.1097/FPC.0b013e3282f55e2e · DOI
- 10.1038/sj.mp.4001353 · DOI
- 10.1053/beem.1999.0046 · DOI · Paper page
- 10.1006/excr.2001.5290 · doi:10.1006/excr.2001.5290
- 10.1083/jcb.200411047 · DOI · Paper page
- 10.1016/j.tins.2009.11.003 · DOI · Paper page
- 10.1385/MN:34:3:205 · DOI · Paper page
- 10.1046/j.1460-9568.1999.00866.x · DOI
- 10.1111/j.1399-5618.2008.00639.x · DOI · Paper page
- 10.1038/npp.2008.103 · DOI
- 10.1073/pnas.1632587100 · DOI · Paper page
- 10.1038/sj.tpj.6500300 · DOI
- 10.1073/pnas.211427898 · DOI · Paper page
- 10.1016/S0091-3057(98)00242-1 · doi:10.1016/s0091-3057(98)00242-1
- 10.2174/138945009789735156 · DOI · Paper page
- 10.1016/j.pnpbp.2007.05.002 · DOI
- 10.1038/sj.npp.1300079 · DOI
- 10.1186/gb-2010-11-5-r48 · DOI · Paper page
- 10.1016/j.pnpbp.2004.06.005 · DOI
- 10.1016/0028-3908(85)90133-9 · DOI
- 10.1007/s002130051140 · DOI
- 10.1523/JNEUROSCI.4376-04.2005 · DOI
- 10.1186/gb-2004-5-10-r80 · DOI · Paper page
- 10.1186/gb-2007-8-9-r183 · DOI · Paper page
- 10.1006/geno.2002.6698 · DOI · Paper page
- 10.1073/pnas.83.24.9827 · DOI · Paper page
Cited by
Glucocorticoid receptor signaling in astrocytes is required for aversive memory formation
Tertil, M., Skupio, U., Barut, J., Dubovyk, V., Wawrzczak-Bargiela, A., Soltys, Z., Golda, S., Kudla, L., Wiktorowska, L., Szklarczyk, K., et al. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0300-x · Cited by 72
Self-citationPatrício, P., Mateus-Pinheiro, A., Irmler, M., Alves, N. D., Machado-Santos, A. R., Morais, M., Correia, J. S., Korostynski, M., Piechota, M., Stoffel, R., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.176 · Cited by 57
Self-citationMolecular profile of dissociative drug ketamine in relation to its rapid antidepressant action
Ficek, J., Zygmunt, M., Piechota, M., Hoinkis, D., Rodriguez Parkitna, J., Przewlocki, R., & Korostynski, M. (2016) · BMC Genomics · doi:10.1186/s12864-016-2713-3 · Cited by 42
“The dissection procedure was performed as previously described [13].”
Self-citation
Metadata
- Authors
- Korostynski, M., Piechota, M., Dzbek, J., Mlynarski, W., Szklarczyk, K., Ziolkowska, B., & Przewlocki, R.
- Venue
- BMC Genomics
- Published
- 2013
- Volume
- 14
- Issue
- 1
- Pages
- 606
- ISSN
- 1471-2164 (ISSN-L)
- OpenAlex
- W2148533858
- Cited by
- 41
- References
- 15
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel drug-regulated transcriptional networks in brain reveal pharmacological properties of psychotropic drugs. https://app.cochat.ai/papers/10.1186/1471-2164-14-606
- The paper
- Korostynski, M., Piechota, M., Dzbek, J., Mlynarski, W., Szklarczyk, K., Ziolkowska, B., & Przewlocki, R. (2013). Novel drug-regulated transcriptional networks in brain reveal pharmacological properties of psychotropic drugs. BMC Genomics. https://doi.org/10.1186/1471-2164-14-606
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.